Skip to main content

BIOLOGY ADVISORY BOARD

The Biology Advisory Board (BAB) serves as an external resource for the leadership, faculty, and students in the Department of Biology at Syracuse University. It is an all-volunteer board composed of eight members who have agreed to serve for two-year terms that may be renewed. The BAB is made up of distinguished scholars, clinicians, and accomplished professionals from the private sector, all sharing a common passion for the department's success. One member has also served on the Board of Visitors of the College of Arts and Sciences for a number of years.

The BAB's primary functions are:

  1. to advise the department's leadership, and, as appropriate, the dean of the College of Arts and Sciences;
  2. to facilitate connections for the current faculty and students with people and resources outside the university, leveraging the experience and networks of BAB members;
  3. to work to promote and enhance connections to the many alumni of the department;
  4. to advocate for the department and its activities inside and outside the University.

The BAB thus provides a valuable two-way conduit of information and opportunities between the University and people and organizations outside the University. Board members meet on campus one to two times per year and, in addition, hold two or three teleconferences among members to work toward the above goals. Previous efforts of the board have been important in advocating for construction of the new Life Sciences Complex (LSC) building, and in aiding the support of key research facilities within it such as the Zeiss LSM 710 Confocal Microscope, housed in the Blatt Imaging Center on the third floor of the LSC. A number of board members have also supported various activities in the department through financial gifts and/ or their time and expertise to help the department provide special opportunities for students that would otherwise not be possible.


Board Co-Chairs:


Laura Feldman

LAURA FELDMAN '81 joined her father's law practice following graduation from the San Antonio Law School at St. Mary's University in 1987, and upon her father's retirement, continued the practice that has grown into Feldman & Pinto, PC, a five-attorney firm in Philadelphia, PA and Southern NJ. The principal focus of the firm is medical malpractice cases throughout the Northeast. Laura graduated from Syracuse University in 1981 with a BS Degree in Biology. While at SU she was also recognized as a member of Alpha Epsilon Delta and Eta Pi Upsilon honoraries. Active in Philadelphia, Laura was elected to the Philadelphia Bar Association's Board of Governors in 2003, and in addition, serves on the Board of Directors of the Philadelphia Trial Lawyers Association. Laura has one son, Jake, and is married to George Patterson.


MICHAEL R. KURMAN '73 has spent more than 30 years in the oncology drug development field. He is a board-certified medical oncologist who practiced community oncology in New Jersey, where he participated as an investigator in oncology clinical trials sponsored by the Eastern Cooperative Oncology Group and the Memorial Adjunct Staff Oncology Group. During his career in the pharmaceutical industry, he has held positions of progressive responsibility at Janssen Pharmaceutica as director of oncology, at Cyotgen Corporation as senior director of research and at U.S. Bioscience as vice president for research. Before establishing his consultancy, Dr. Kurman served as vice president for clinical and scientific operations for Quintiles' Oncology Therapeutics Division. In his 24-year career in the pharmaceutical industry, Dr. Kurman has been involved in the regulatory review or commercial launch of four new oncology products. He received his bachelor's degree summa cum laude in biology from SU and his M.D. degree from Cornell University Medical College. He received his training in internal medicine at SUNY Upstate Medical University and his oncology training at Mount Sinai Medical Center in New York City. Dr. Kurman has served on the scientific advisory boards of several companies and as well on as the boards of Avalon Pharmaceuticals and Thallion Pharmaceuticals. He is president of the Upper Saddle River Board of Health and a member of several professional societies.

Board Members:


GHALEB DAOUK '79 is a pediatric nephrology consultant at Boston Children's Hospital and assistant professor of pediatrics at Harvard Medical School. After graduating from SU's College of Arts and Sciences magna cum laude with a bachelor's degree in biology, Daouk earned his M.D. degree from the American University of Beirut, followed by a master's degree in management of technology from the Massachusetts Institute of Technology Sloan School of Management. As a postdoctoral research fellow of the American Heart Association at MIT, he cloned the gene for the brain creatine kinase. The discovery lead him to co-found, with his wife, Rima Kaddurah-Daouk, the biotechnology company Avicena, currently located in Palo Alto, California. He completed his clinical speciality training in pediatrics and nephrology at Massachusetts General Hospital in Boston. He is an active member of the College of Art and Sciences' Board of Visitors, a diplomat of the American Board of Pediatrics, and a member of several medical societies.


ROBERT HALLENBECK, G'80, G'82 is vice president for BD Biosciences Advanced Bioprocessing unit. Bob joined BDAB in Baltimore in January 2010 and is responsible for the strategy, performance and operations of the Advanced Bioprocessing unit and heads the unit's leadership team. Becton Dickinson is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BDAB develops, manufactures, and markets cell culture media and supplements that are used as critical components in the production of some of the most widely used drugs and vaccines on the global market today. Hallenbeck has two degrees from SU: an M.S. in biology and a J.D. While studying for these degrees, he was a teaching assistant in both the biology and mathematics departments. He holds a B.S. in biology from St. Lawrence University. After graduation from SU, he practiced law in Rochester at Nixon Peabody. In 1987, he joined BD in New Jersey and served as associate chief patent counsel, associate general counsel, and vice president and general counsel. More recently, he held the position of vice president, business development and strategic investments. A registered patent attorney, he is also vice chairman of the Board of Trustees of Fairleigh Dickinson University.


MARK HOROWITZ '72 is a professor of orthopedics and rehabilitation and vice chair for research at Yale School of Medicine. After graduation with a B.S. in biology from SU, he earned his Ph.D. from the State University of New York Upstate Medical University in 1977. He was a postdoctoral fellow in immunology at Yale School of Medicine, where he was appointed assistant professor and moved through the faculty ranks to full professor. He serves as director for the Orthopaedic Histology and Histomorphometry Laboratory and co-director and cell core director of the Yale Core Center for Musculoskeletal Disorders. Professor Horowitz's research focus is in osteoimmunology, defining the interactions between the skeletal, hematopoietic, and immune systems (using genetic mutations, analysis of osteoclast, and osteoblast development mediated by transcription factors and cytokines associated with the immune system). His research is directed at understanding the origin, differentiation, and function of marrow adipose tissue, which is different from white or brown fat. He has been the recipient of many research honors and awards, including the American Society for Bone and Mineral Research (ASBMR) Young Investigator Award, the Swebilius Cancer Research Award, and the Andrew W. Mellon Foundation Award. He is a member of ASBMR and the Orthopaedic Research Society, as well as a member of the editorial board of Adipocyte. Throughout his career he has served on grant and program review panels for the National Institutes of Health, the National Science Foundation, the Department of Veterans Affairs, the United States-Israel Binational Science Foundation, the Israel Academy of Sciences and Humanities, U.S. Army Medical Research and Material Command, and The Wellcome Trust.


JEFFREY MCMULLEN '73 s vice chairman of inVentiv Health. He previously served as president and chief executive officer of PharmaNet Development Group, which he co-founded in 1996. PharmaNet is now part of inVentiv Health's clinical division. He has nearly 40 years of drug development experience on a global basis. His career includes 30 years with major drug development services companies with responsibilities in operations, executive management, and at the board level. Before that, he worked for a major pharmaceutical company in the clinical, regulatory, and drug metabolism areas. He holds a B.S. in biology from Syracuse University.


DAVID PAGE '78 is medical director of the Accountable Care Coalition of Syracuse, an accountable care organization that contracts with Medicare under the Medicare Shared Savings program. Before this role, Dr. Page was president of Family Care Medical group for 17 years. The group grew from 16 to 65 physicians in that time, adopted electronic medical records in 1999, and developed several innovative programs to help control health care costs and to keep physicians in a leadership role as health care has evolved. Meaningful use in the first year of eligibility and Level III patient-centered medical homes are other achievements in patient service of Family Care Medical Group during Dr. Page's tenure. During this time he has also maintained a full-time medical practice in family medicine. Dr. Page is a past president of the Onondaga County Medical Society and serves as an officer on the executive committee of the Health Collaborative of Central New York. The father of three, he enjoys hiking, skiing, scuba diving, and photography.